Their findings were in good agreement with ours to some extent, but we further determined in HCC that (1) the regulation of SLC7A11 by IGF2BP2 was m6A-dependent by RIP-qPCR of mutations in the structural domain of IGF2BP2, (2) identified the key m6A modification sites (+1795) that regulate the expression of SLC7A11 and (3) reversible regulation of SLC7A11 expression by m6A was confirmed by overexpression of ALKBH5. Here, SLC7A11 is linked to hepatocellular carcinoma.